🇺🇸 FDA
Patent

US 10443052

Compositions for modulating C9ORF72 expression

granted A61PA61P25/00A61P25/16

Quick answer

US patent 10443052 (Compositions for modulating C9ORF72 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
82
CPC classes
A61P, A61P25/00, A61P25/16, A61P25/28, A61P43/00